In vitro interactions between interleukin (IL)-12, interferon (IFN)-y, and human immunodeficiency virus (HIV) type 1 infection in human macrophages were examined. Macrophages were infected with HIV-l and cocultured with autologousmonocyte-depleted peripheral blood mononuclear cells(pBMC). The addition of autologous PBMC to HIV-1-infected macrophages resulted in an expansive increase in reverse transcriptase (RT) activity; however, when both autologous PBMC and IL-12 were added, RT activity decreased (75%-90%) and high levelsof IFN-y (9-16 nglmL) were detected. The addition of anti-IFN-y antibodies blocked the IL-12-induced decrease in RT activity. Surprisingly, exogenous IL-12 added to HIV-infected macrophage cultures without autologouslymphocytes resulted in a 50%-60% reduction in RT activity and no detectable increase in IFN-y. The addition of anti-IFN-y did not inhibit this IL-12-mediated effect. These results suggest that IL-12 is capable of indirectly downregulatingHIV proliferationin macrophagecultures reconstitutedwith autologousPBMC and of directly suppressing HIV replication in purified macrophage cultures.
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Interleukin (IL)-12 was initially described as a natural killer cell stimulatory factor and a cytotoxic lymphocyte maturation factor [1, 2] . This multifunctional cytokine (produced by macrophages and B cells) elevates natural killer and cytotoxic T cell activity, increases T cell proliferation, and up-regulates the production of interferon (IFN)-y [3] . In the murine model, administration ofIL-12 up-regulates NK cell activity, increases the serum level of IFN-y, increases the production of IgG2a, decreases IgG 1 production, and results in a shift toward a Thl response to specific antigens and pathogens [1, [3] [4] [5] [6] . As for interactions between IL-I2 and AIDS, previous studies have indicated there is an impaired production of IL-I2 in human immunodeficiency virus (HIV)-infected patients, and addition of exogenous IL-12 in vitro can restore HIV -specific cell-mediated immune responses in HIV-positive persons [7, 8] .
Clerici et a1. [7] noted that peripheral blood mononuclear cells (PBMC) from AIDS patients lacked T cell proliferation and IL-2 production when exposed to HIV envelope proteins or influenza virus. However, these responses could be restored by addition of IL-I2. They also noted that IFN-y production was diminished in PBMC of AIDS patients stimulated with phytohemagglutinin and that IL-I2 could restore IFN -y production. IL-I2 could not augment the production of IFN-y in stimulated PBMC from normal donors. Because of the close interactions between IL-I2, IFN-y, and HIV-I, we examined the effects of IL-I2 on HIV-I in human macrophages with and without the reconstitution of the cultures with autologous PBMC.
Materials and Methods
Preparation ofvirus stocks. Virus stocks were prepared using a modification of a published method [9] . Briefly, virus containing cell supernatants from PBMC was centrifuged (250 g, 20 min) to remove cell debris. The clarified virus suspension was then ultracentrifuged (41,460 g, 2 h) through a sucrose cushion in 10 mMTRIS hydrochloride (pH 7.4),1 mMEDTA, and 0.1 MNaCl to ensure that cytokines in the supernatant were removed. The HIV-l pellet was then resuspended in RPMI with 5% fetal bovine serum (FBS) and maintained at -80°C. Virus stocks were tested (Mycoplasma Rapid Detection Kit; GEN-PROBE, San Diego) and were negative for mycoplasma.
Infection of macrophages with HIV-l. PBMC were isolated from the blood of HIV-Iv-negative persons by ficoll-hypaque. Monocytes were prepared from PBMC by centrifugation through discontinuous Percoll gradients. Isolation of PBMC-derived monocytes, following Ficoll and Percoll gradients and adherence, results in 98% monocyte purity [10] . The remaining PBMC, depleted of the monocyte fraction «5% monocytes by FACS; Becton Dickinson, San Jose, CA) were frozen in liquid nitrogen until needed. Monocytes (10 6 cells/mL [200 j.lL]/well) were cultured in 96-well flat-bottom plates in endotoxin-free « 10 pg/mL) RPMI 1640 (BioWhittaker, Walkersville, MD) with endotoxin-free « 10 pg/ mL) 5% FBS (GIBCO, Gaithersburg, MD) and incubated 5 days (37°C in 5% CO 2 ) to allow maturation into macrophages. On day 6 after isolation, predetermined groups of macrophages were exposed to HlV BaL (reverse transcriptase [RT] activity 60,000 cpm/ mL containing < 10 pg/mL endotoxin) or complete medium for 3 h at 37°C (5% CO 2 in air). The virus or medium was then removed and replaced with fresh complete medium. PBMC without mono-JID 1996; 173 (March) cytes were thawed and added back to select groups of infected macrophages (0.5-1.0 X 10 6/well).
Effects of exogenous cytokine on HIV replication.
In some experiments, macrophages or macrophages plus PBMC, plated on a 96-well plate and infected as described above, were given recombinant human (rHu) IL-12 (10 ng/mL; Immunex, Seattle) 3 h after HIV infection. rHuIL-I2 was tested for and found to be negative for endotoxin. In some experiments, an anti-IFN-y murine monoclonal antibody (1:50 dilution; Chemicon, Temecula, CA) was added 12 h after infection to some cell cultures with and without IL-12. Cell cultures were maintained by replenishing RPMI 1640 and 5% FBS every 4 days. On days 8, 12, and 14 after infection, 20-pL samples from each culture well were analyzed for HIV RT activity by RT assay [II] . In parallel cultures, a nonspecificmurine IgG was added in place of the anti-IFN antibody as an essential control.
IFN-y ELISA. Culture supernatants were harvested 72 h after infection and stored at -80°C until assay. A sandwich IFN-y ELISA, linear from 0 to 20 ng/mL with a sensitivity to 5 pg/mL, was used to determine the level of IFN-y within the cell culture supernatants. Antibodies for the assay were purchased from Chemicon and used according to the manufacturer's instructions.
Results
Macrophages are key cells in immune regulation and a primary target for HIV-I infection [12] [13] [14] [15] . We initiated a series of experiments to determine whether the levels of HIV-I replication in infected macrophage cultures could be altered by the addition of rHuIL-I2. Purified monocyte-derived macrophage cultures infected with a monocytotropic HIV isolate (HIVBad had levels of viral infection of 70%-90% of total cells and syncytial formation evident within 5-1 0 days after infection. As previously documented, a temporal increase in HIV-I RT activity was observed in infected macrophage cultures at 8, 12, and 14 days after infection [16, 17] . Neither cytopathic effects nor RT levels were detected in uninfected macrophage cultures.
Effects of IL-I 2 on HIV-I replication in infected macrophages reconstituted with autologous PEMe. Because IL-I2 increases the production of IFN-y, a macrophage-activating cytokine, we did experiments to determine the effects of exogenous IL-I2 on HIV-infected macrophages. In the first set of experiments, HIV-infected macrophage cultures were reconstituted with monocyte-depleted autologous PBMC, rHuIL-12 was added, and RT activity was measured 8, 12, and 14 days after infection. As previously observed [16, 17] , HIV-infected macrophages had elevated RT activity readily detectable by 8 days after infection (figure 1). During the course of the experiment, HIV-I-infected macrophages reconstituted with PBMC (macrophage-PBMC) had greater RT activity than HIV-infected macrophages without PBMC (figure 1). The addition of rHuIL-I2 to infected macrophage-PBMC cultures resulted in 75%-90% suppression ofRT activity in all 6 donors examined. This decrease in RT activity was maintained during the 14-day observation period (figure 1). The ability of IL-12 to induce the production of IFN-y by T cells and NK cells has been documented [3, 4] . Because of our observation on the down-regulating effects of rHuIL-12 on HIV-I and the known ability of IFN-y to activate macrophagekilling mechanisms, the level of IFN-y in culture supernatants was determined. IFN-y could not be detected in HIV-l-infected macrophage cultures (figure 2). In the 72-h cell supernatant from macrophage cultures reconstituted with autologous PBMC, we detected levels ofIFN-y of 0-2 ng/mL. The background levels of IFN-y «2 ng/mL) observed in 2 of 6 donors was not sufficient to suppress RT activity in these donors (figure I) . In all cultures to which both PBMC and IL-12 were added, higher levels of IFN-y (10-16 ng/mL) were detected (figure 2). As previously reported, IL-12 also induced IFN-y in normal PBMC (data not shown) [3, 18, 19] .
Effect of antibody to IFN-y on the IL-12-induced downregulation of HIV-I. IFN-y can activate macrophages in vitro, resulting in decreased HIV-I replication in vitro [20] . Because addition of IL-12 to macrophages to which autologous PBMC were added resulted in decreased HIV-l RT and increased IFN-y, experiments were done to determine whether the addition of an antibody to IFN-y would abrogate the antiviral effects of IL-12. A monoclonal antibody to IFN-y was added to cultures containing HIV-infected macrophage-PBMC and IL-12. Eight days after infection, we analyzed the supernatants for RT activity. The results, presented in figure 3 , demonstrate that the down-regulation of HIV RT by IL-12 was blocked by anti-IFN-y. The IL-12 effect was not inhibited by the addition of the control antibody.
Effects of IL-12 on HIV-I replication in macrophage cultures.
Although IL-12 can be produced by macrophages and . Indirectly, IL-12 subsequently broadens its effect on the immune system by inducing IFN-y production [1, 18, 19] . IFN-y then interacts directly with IFN-y-dependent cells to activate inflammatory pathways and additional immune responses. These up-regulatory functions of IL-12 suggest that this cytokine has antipathogenic functions. In fact, in parasiteinfected mice, IL-12 treatment decreases the level of several organisms including Leishmania major [23, 24] , Toxoplasma gondii [25] , and cryptococci [4] . In the earlier studies, the reduction in pathogen burden seemed to be linked to the IL-12 induction of IFN-y that leads to the activation of macrophage functions, including killing mechanisms. Depletion of the IL-12-induced IFN-y, either by addition of an antibody to IFNy or removal of NK cells, blocks the antimicrobial effects of IL-12 [23, 24, 26] . There is also evidence that the antimicrobial properties of IL-12 occur because of an IL-12-induced shift in the Thl-Th2 ratio to that of the Th1 subset, thus augmenting antipathogenic mechanisms.
In addition to an antiparasitic effect, IL-12 may also have a role in regulating the immune system during viral infection. For instance, in mice infected with lymphocytic choriomeningitis virus, addition of IL-12 leads to an increase or a decrease in the virus-specific cytotoxic T lymphocyte response, CD8 T cell JID 1996;173 (March) Average RT activity from 3 donors (1-3) was determined from triplicate samples from HIY-infected macrophage cultures (medium), HIYinfected macrophage cultures plus recombinant human (rHu) IL-12 added once immediately after infection (+IL-12), and HlV-infected macrophage cultures plus rHu1L-12 and anti-IFN-y mAb (+IL-12+ IFNymAb). Addition of control mAb to HIY-infected cells supplemented with lL-12 had no effect on IL-\2-induced decrease in RT activity. Decreased RT activity was maintained until end ofexperiment (14 days after infection).
+IL-12+IFNymAb
ity. In a previous study of murine macrophages, the addition of autologous cells and IL-12 to macrophage cultures also resulted in an increase in immunologic activity [3] . The activation in the murine model seems to be linked to IL-12 induction of IFN-y that then energizes the killing mechanisms. In the present study, an increase in IFN-y concentration coincided with the decrease in HIV RT following the addition of IL-12 levels, and viral replication, depending upon the amount of IL-12 administered [3] . The dose-dependent effect of IL-12 on other viral pathogens has not yet been determined. However, a recent study of AIDS patients indicated that IL-12 is capable of restoring cell-mediated immune responses against HIV in vitro [7] . In that study, the suppression of T cell proliferation and IL-2 production in response to influenza virus and HIV envelope proteins in asymptomatic persons could be reversed by the addition of IL-12 to these cell cultures.
In the current study, we demonstrated that IL-12 is capable of down-regulating HIY-1 replication in macrophage cultures reconstituted with autologous PBMC by decreasing RT activ- to reconstituted human cell cultures. This indicates that the IFN-y induced by IL-12 in Hl'V-infected human cell cultures may be responsible for the observed down-regulation in HlV activity. In support of this idea, similar to the observations in murine studies, the addition of an anti-IFN-y antibody blocked the IL-12 reduction in RT activity in infected macrophage-PBMC cultures. This indicates that an IFN-y-dependent mechanism is functioning to down-regulate HlV by up-regulating macrophage activity.
The addition ofIL-12 to Hl'V-infected macrophage cultures alone was unexpectedly capable of down-regulating Hlv-I in the absence of autologous PBMC through which IL-12 activates IFN-y production. Although IL-12 can affect NK and T cells, no direct IL-12 effects have been observed regarding macrophages nor have IL-12 receptors been detected on the macrophage surface [3] . In macrophage cultures to which IL-12 was added, little or no IFN-y was detected. Also, the addition of an antibody to IFN-y to the macrophage cultures could not block the IL-12-mediated down-regulation of HIV RT that was observed when the antibody was added to cultures containing macrophage-PBMC and IL-12. The IFN-y -independent mechanism induced by IL-12 is not known and is being investigated. Although human macrophages are not known to have IL-12 receptors, it is possible that IL-12 receptors may be up-regulated on the surface of macrophages as the direct result of Hlv-1 infection. The concept that HfV-1 infection could up-regulate IL-12 receptors or other cytokine receptors is not without precedence: A prior study showed that mv can control signaling pathways through a selective increase of tumor necrosis factor surface receptors. [27] . It is unlikely that the decrease in HIV replication was indirectly due to an increase of monokines (e.g., IL-6, tumor necrosis factor-a, or granulocyte-macrophage colony-stimulating factor), because these cytokines can increase mv-I replication in human macrophages in vitro [28] [29] [30] . However, it remains possible that IL-12 may act via other unknown cytokine-effector mechanisms and that macrophages infected with primary HIV isolates or macrophages from HIVpositive subjects may respond differently to 1L-12 than macrophages infected with HlV laboratory isolates. Therefore, whether IL-12 induces other monokines or activates other macrophage functions in HIV-infected macrophages from HlVpositive and -negative subjects vaccinated with candidate HlV vaccines is the current focus of our research.
